
Opinion|Videos|July 8, 2024
Switching Treatments in Spinal Muscular Atrophy
Key opinion leaders share their strategies for discussing potential changes in therapy and transitioning between treatments with patients, emphasizing the importance of reassuring patients that such changes are intended to provide long-term benefits for managing their spinal muscular atrophy.
Advertisement
Episodes in this series

- How would you approach a discussion about a change in therapy?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Apitegromab for Spinal Muscular Atrophy
2
8 Emerging Therapies Shaping the Muscular Dystrophy Treatment Landscape
3
AAN, AHS Issue Updated Guideline on Migraine Prevention, Atogepant Meets End Points in Phase 3 Trial, Trientine Enters Phase 3 Trial
4
Exploring the Link Between Football Players and ALS: Rory Siegel, DO
5










